Recruiting

Phase 3

PovorcitinibRollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Sponsor:

Incyte Corporation

Code:

NCT06855498

Conditions

Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

povorcitinib

Study Details

Brief summary:

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Conditions

Hidradenitis Suppurativa (HS)

Study ID

NCT06855498

Start date

Feb 28, 2025

Status verified date

Aug, 2026

Completion date

Feb 28, 2028

Anticipated

Primary completion date

Feb 28, 2028

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Ability to comprehend and willingness to sign a written ICF for the study.
Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
Willingness to avoid pregnancy or fathering children as defined in the protocol.
Willingness and ability to comply with the study Protocol and procedures.

Exclusion Criteria:

Had been permanently discontinued from study treatment during the parent study.
Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:

Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
Live, attenuated vaccine.
Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Design

Enrollment

600 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: povorcitinib

Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.

Interventions

povorcitinib

Study drug will be taken orally as defined by the protocol.

Primary outcome measure

Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 3 years ]

Central Contacts and Locations

Central contacts

Incyte Corporation Call Center (US)

1.855.463.3463 medinfo@incyte.com

Incyte Corporation Call Center (ex-US)

+800 00027423 eumedinfo@incyte.com

Locations

Investigative Site US086

Recruiting

Birmingham, Alabama, United States, 35244

Investigative Site US004

Recruiting

Phoenix, Arizona, United States, 85006

Investigative Site US076

Recruiting

Fountain Valley, California, United States, 92708-3701

Investigative Site US077

Recruiting

Fremont, California, United States, 94538

Investigative Site US071

Recruiting

Huntington Beach, California, United States, 92647

Investigative Site US097

Recruiting

Irvine, California, United States, 92697

Investigative Site US020

Recruiting

Laguna Niguel, California, United States, 92677

Investigative Site US036

Recruiting

Los Angeles, California, United States, 90033

Investigative Site US067

Recruiting

Los Angeles, California, United States, 90045

Investigative Site US060

Recruiting

Northridge, California, United States, 91325

Investigative Site US037

Recruiting

Oakland, California, United States, 94611

Investigative Site US089

Recruiting

Santa Monica, California, United States, 90403

Investigative Site US080

Recruiting

Sherman Oaks, California, United States, 91403

Investigative Site US002

Recruiting

Boca Raton, Florida, United States, 33486

Investigative Site US084

Recruiting

Coral Gables, Florida, United States, 33146

Investigative Site US017

Recruiting

Hialeah, Florida, United States, 33012

Investigative Site US019

Recruiting

Hollywood, Florida, United States, 33021-6746

Investigative Site US062

Recruiting

Miami, Florida, United States, 33126

Investigative Site US015

Recruiting

Miami, Florida, United States, 33136

Investigative Site US072

Recruiting

Miami Lakes, Florida, United States, 33014

Investigative Site US079

Recruiting

Miami Lakes, Florida, United States, 33014

Investigative Site US023

Recruiting

North Miami Beach, Florida, United States, 33162

Investigative Site US029

Recruiting

Ocala, Florida, United States, 34470

Investigative Site US035

Recruiting

Tampa, Florida, United States, 33607

Investigative Site US005

Recruiting

Tampa, Florida, United States, 33613

Investigative Site US001

Recruiting

Tampa, Florida, United States, 33615

Investigative Site US066

Recruiting

West Palm Beach, Florida, United States, 33401

Investigative Site US070

Recruiting

West Palm Beach, Florida, United States, 33401

Investigative Site US051

Recruiting

Marietta, Georgia, United States, 30060-1047

Investigative Site US093

Recruiting

Chicago, Illinois, United States, 60657

Investigative Site US039

Recruiting

West Dundee, Illinois, United States, 60118

Investigative Site US008

Recruiting

Indianapolis, Indiana, United States, 46250

Investigative Site US064

Recruiting

West Lafayette, Indiana, United States, 47906

Investigative Site US012

Recruiting

Baton Rouge, Louisiana, United States, 70809

Investigative Site US057

Recruiting

New Orleans, Louisiana, United States, 70115

Investigative Site US038

Recruiting

Baltimore, Maryland, United States, 21287-0876

Investigative Site US030

Recruiting

Boston, Massachusetts, United States, 02215

Investigative Site US048

Recruiting

Brighton, Massachusetts, United States, 02135

Investigative Site US061

Recruiting

Ann Arbor, Michigan, United States, 48103

Investigative Site US091

Recruiting

Troy, Michigan, United States, 48084

Investigative Site US042

Recruiting

Waterford, Michigan, United States, 48328

Investigative Site US011

Recruiting

Minneapolis, Minnesota, United States, 55455

Investigative Site US088

Recruiting

Saint Joseph, Missouri, United States, 64506

Investigative Site US016

Recruiting

St Louis, Missouri, United States, 63110

Investigative Site US007

Recruiting

Portsmouth, New Hampshire, United States, 03801

Investigative Site US082

Recruiting

East Syracuse, New York, United States, 13057

Investigative Site US034

Recruiting

New York, New York, United States, 10028-3135

Investigative Site US081

Recruiting

New York, New York, United States, 10075

Investigative Site US065

Recruiting

New York, New York, United States, 10128

Investigative Site US075

Recruiting

New York, New York, United States, 10956

Investigative Site US031

Recruiting

Chapel Hill, North Carolina, United States, 27516

Investigative Site US028

Recruiting

Bexley, Ohio, United States, 43209

Investigative Site US025

Recruiting

Cincinnati, Ohio, United States, 45219

Investigative Site US073

Recruiting

Columbus, Ohio, United States, 43215

Investigative Site US085

Recruiting

Oklahoma City, Oklahoma, United States, 73170

Investigative Site US069

Recruiting

Plymouth Meeting, Pennsylvania, United States, 19462

Investigative Site US021

Recruiting

Bellaire, Texas, United States, 77401

Investigative Site US078

Recruiting

Dallas, Texas, United States, 75230

Investigative Site US010

Recruiting

Dallas, Texas, United States, 75246

Investigative Site US083

Recruiting

San Antonio, Texas, United States, 78218

Investigative Site US068

Recruiting

Webster, Texas, United States, 77598

Investigative Site US063

Recruiting

South Jordan, Utah, United States, 84095

Investigative Site US027

Recruiting

Norfolk, Virginia, United States, 23502

Investigative Site US094

Recruiting

Richmond, Virginia, United States, 23226

Investigative Site US003

Recruiting

Spokane, Washington, United States, 99202

Investigative Site CA008

Recruiting

Calgary, Alberta, Canada, T3E 0B2

Investigative Site CA005

Recruiting

Edmonton, Alberta, Canada, T6G 1C3

Investigative Site CA003

Recruiting

Winnipeg, Manitoba, Canada, R3M 3Z4

Investigative Site CA004

Recruiting

Barrie, Ontario, Canada, L4M 7G1

Investigative Site CA030

Recruiting

Cobourg, Ontario, Canada, K9A 0Z4

Investigative Site CA002

Recruiting

London, Ontario, Canada, N6H 5L5

Investigative Site CA022

Recruiting

Markham, Ontario, Canada, L3P 1X3

Investigative Site CA016

Recruiting

Mississauga, Ontario, Canada, L4Y 4C5

Investigative Site CA001

Recruiting

Peterborough, Ontario, Canada, K9J 5K2

Investigative Site CA010

Recruiting

Richmond Hill, Ontario, Canada, L4B 1L1

Investigative Site CA017

Recruiting

Toronto, Ontario, Canada, M2N 3A6

Investigative Site CA018

Recruiting

Toronto, Ontario, Canada, M3H 5Y8

Investigative Site CA021

Recruiting

Toronto, Ontario, Canada, M4W 2N4

Investigative Site CA019

Recruiting

Waterloo, Ontario, Canada, N2J 1C4

Investigative Site CA020

Recruiting

Québec, Quebec, Canada, G1V4X7

Investigative Site CA026

Recruiting

Québec, Quebec, Canada, G1W 4R4

Investigative Site CA015

Recruiting

Saskatoon, Saskatchewan, Canada, S7K 2C1

More Information

Sponsor

Incyte Corporation

Last update posted

Aug 6, 2026

Last verified

Aug, 2026

Keywords

INCB054707
povorcitinib
Hidradenitis Suppurativa
Hidradenitis
HS

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-08-06.